#### **Supplementary Material:**

# A c-Myc regulatory subnetwork from human transposable element sequences

Jiangrong Wang, Nathan J. Bowen, Leonardo Mariño-Ramírez and I. King Jordan

Supplementary Figure 1. **c-Myc binding site position frequency matrices (PFMs) and sequence logos.** A) V\$CMYC\_01 is the TRANSFAC PFM for c-Myc alone. B) V\$CMYC\_01 is the TRANSFAC PFM for the c-Myc heterodimer.

	Residue Count			
Position	Α	С	G	т
1	7	1	7	3
2	16	0	2	2
3	1	16	4	0
4	0	21	0	0
5	21	0	0	0
6	0	21	0	0
7	0	0	21	0
8	0	0	0	21
9	0	0	21	0
10	0	13	6	1
11	1	2	0	15
12	3	11	0	1

#### A) V\$MYC\_01

#### B) V\$MYC\_02

	Residue Count			
Position	Α	С	G	т
1	2	0	8	6
2	13	1	3	0
3	0	16	3	0
4	0	19	0	0
5	19	0	0	0
6	0	19	0	0
7	0	0	19	0
8	0	0	0	19
9	0	0	19	0
10	0	7	10	1
11	0	6	0	7
12	0	5	1	3





Supplementary Table 1. Number of TEs that contain c-Myc binding sites for each TE class/family. Based on Clover run with P<0.001.

TE class/family <sup>a</sup>	Observed number <sup>b</sup>	Observed percent <sup>c</sup>	Expected percent <sup>d</sup>
L1	173	21.2%	21.9%
L2	115	14.1%	9.7%
LINE other	8	1.0%	1.6%
Alu	108	13.2%	28.1%
MIR	158	19.4%	13.9%
SINE other	9	1.1%	0.1%
DNA	90	11.0%	9.3%
LTR	155	19.0%	15.5%
Total	816	100.00%	100.0%

<sup>a</sup>Name of TE class or family. LINE other means LINE elements excluding L1 and L2; SINE other means SINE elements excluding Alu and MIR

<sup>b</sup>Observed number of TEs in each class/family

<sup>c</sup>Observed percent: the observed number of TEs in each class/family divided by the total observed number (816) of TEs containing c-Myc binding sites \* 100

<sup>d</sup>Expected percent: the total number of TEs in each class/family in human genome divided by the total number of all TEs in human genome \* 100

#### Supplement: TE-derived c-Myc regulatory subnetwork

Wang et al.

Supplementary Figure 2. Family origins and relative ages for human TEs bound by c-Myc. A) Observed versus expected relative percentages of c-Myc binding sites derived from different classes/families of human TEs. Based on Clover run with *P*<0.001. B) Percent divergence from subfamily consensus sequences for human TEs that are bound by c-Myc.



Supplementary Table 2. Over-expressed tissues of c-Myc and TE-derived target genes. Based on permutations test (P value = 0.05).

c-Myc over-expressed tissues	P value
BM-CD105+ endothelial	0.0034
BM-CD34+	0
PB-CD4+ Tcells	0.0007
PB-CD8+ Tcells	0.0086
PB-CD19+ Bcells	0.0007
leukemia lymphoblastic(molt4)	0.0001
721 B lymphoblasts	0
leukemia promyelocytic(hl60)	0.0052
lymphoma Burkitts Daudi	0
leukemia chronic myelogenous(k562)	0.0001
colorectal adenocarcinoma	0.0174
bronchial epithelial cells	0.0001
TE-derived c-Myc target genes' over-expressed tissues	P value
fetal brain	0.036
whole brain	0.009
prefrontal cortex	0
amygdala	0.001
hypothalamus	0
thalamus	0
spinal cord	0.003
BM-CD33+ myeloid	0
BM-CD34+	0
whole blood	0
PB-BDCA4+ dentritic cells	0
PB-CD14+ monocytes	0
PB-CD56+ NKCells	0
PB-CD4+ Tcells	0.001
PB-CD8+ Tcells	0
PB-CD19+ Bcells	0
721 B lymphoblasts	0
lymphoma Burkitts Raji	0
lymphoma Burkitts Daudi	0
thyroid	0.003
smooth muscle	0
placenta	0.019

Supplementary Figure 3. **Over-expression of c-Myc and TE-derived target genes.** Based on permutations test. A) Example of a comparison between randomly permuted 721 B lymphoblast expression levels and observed c-Myc and TE-derived c-Myc target genes 721 B lymphoblast expression levels. B) Results of the permutation test for c-Myc across all 79 tissues [-In*P*-values]. C) Results of the permutation test for TE-derived c-Myc taget genes across all 79 tissues [-In*P*-values]. Significance threshold levels are indicated for panels B & C.



Supplementary Table 3. Enriched annotations of target genes derived from specific **TE-class/family.** Based on gene set enrichment analysis using MsigDB.

Genes with Alu derived c-Myc binding sites			
Functional annotations	P value		
Biopolymer metabolic process	4.78E-19		
Nucleus	1.58E-17		
Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process	8.04E-14		
Biopolymer modification	4.48E-12		
Cytoplasm	4.92E-12		
Protein metabolic process	1.05E-11		
Protein modification process	1.91E-11		
RNA metabolic process	3.22E-9		
Post translational protein modification	4.45E-9		
Stem cell embryonic up	3.08E-8		
Genes with L1 derived c-Myc binding sites			
Functional annotations	P value		
Targets of MicroRNA TTGCACT, MIR-130A, MIR-301, MIR-130B	2.42E-9		
Down-regulated at any timepoint following treatment of XPB/CS fibroblasts with 3 $\ensuremath{J}\xspace{-1mu}$ UVC	1.49E-8		
Targets of MicroRNA GCACTTT, MIR-17-5P, MIR-20A, MIR-106A, MIR-106B, MIR-20B, MIR-519D	1.59E-7		
Up-regulated in mouse hematopoietic late progenitors from adult bone marrow	1.09E-6		
Kinase activity	1.16E-5		
Nucleus	1.36E-5		
Chromatin modification	1.98E-5		
Protein serine threonine kinase activity	2.88E-5		
Transferase activity transferring phosphorus containing groups	3.06E-5		
Targets of MicroRNA GTGCAAT, MIR-25, MIR-32, MIR-92, MIR-363, MIR-367	3.25E-5		
Targets of MicroRNA CTATGCA, MIR-153	4.14E-5		

Supplementary Table 3 (Continued). Enriched annotations of target genes derived from specific TE-class/family. Based on gene set enrichment analysis using MsigDB.

Genes with L2 derived c-Myc binding sites			
Functional annotations	P value		
Lymphoma and immune response expression clusters (Module_126)	1.63E-7		
Targets of MicroRNA AAGTCCA, MIR-422B, MIR-422A	5.44E-7		
Cytoplasm	7.07E-7		
Downregulated in correlation with overt Alzheimer's Disearse, in the CA1 region of the hippocampus	9.83E-7		
Enriched in mouse neural stem cells, compared to differentiated brain and bone marrow cells	2.08E-6		
Plasma membrane	2.55E-6		
Targets of MicroRNA ACATTCC, MIR-1, MIR-206	4.7E-6		
Membrane	5.85E-6		
Genes with promoter regions around transcription start site containing the motif which matches annotation for MAZ: MYC-associated zinc finger protein	9.7E-6		
Enriched in mouse embryonic stem cells, compared to differentiated brain and bone marrow cells	3.34E-5		
Plasma membrane	4.25E-5		
Neighborhood of MAX	4.47E-5		
Transport	5.92E-5		
Genes with MIR derived c-Myc binding sites			
Functional annotations	P value		
Cytoplasm	2.81E-6		
Membrane	3.77E-6		
Module_188 (Clinical annotaion: B lymphoma is enriched in this module)	5.25E-6		
Receptor activity	1.6E-5		
Biopolymer metabolic process	1.91E-5		
Protein metabolic process	3.02E-5		
Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process	3.4E-5		
Nucleus	3.91E-5		

Supplementary Table 3 (Continued). Enriched annotations of target genes derived from specific TE-class/family. Based on gene set enrichment analysis using MsigDB.

Genes with DNA derived c-Myc binding sites				
Functional annotations	P value			
Down-regulated at any timepoint following treatment of XPB/TTD fibroblasts with 3 J/m^2 UVC	3.96E-7			
Targets of MicroRNA AATGTGA, MIR-23A, MIR-23B	1.45E-5			
Phosphoric monoester hydrolase activity	6.04E-5			
Up-regulated in correlation with overt Alzheimer's Disease in the CA1 region of the hippocampus	7.91E-5			
Downregulated by both Et-743 and Pt-650 in HCT116 cells	7.99E-5			
Genes involved in MAPK signaling pathway	1.21E-4			
Targets of MicroRNA TGCACTG, MIR-148A, MIR-152, MIR-148B	2.72E-4			
Genes up-regulated in PMNs upon migration to skin lesions	4E-4			
Double stranded RNA binding	4.67E-4			
Enriched in mouse neural stem cells, compared to differentiated brain and bone marrow cells	4.92E-4			
Genes with LTR derived c-Myc binding sites				
Functional annotations	P value			
Down-regulated at any timepoint following treatment of XPB/CS fibroblasts with 3 $J/m^{2}$ UVC	1.75E-8			
Cytoplasm	8.3E-8			
Targets of MicroRNA TGAATGT, MIR-181A, MIR-181B, MIR-181C, MIR-181D	9.77E-6			
Targets of MicroRNA TAGCTTT, MIR-9	1.15E-5			
Targets of MicroRNA AAGCACA, MIR-218	2.36E-5			
Targets of MicroRNA CATTTCA, MIR-203	3.6E-5			
Genes whose expression is induced in human mast cells by lipopolysaccharide treatment	4.77E-5			
Targets of MicroRNA CAGTATT, MIR-200B, MIR-200C, MIR-429	6.2E-5			
Module_136 (Clinical annotaion: B lymphoma is enriched in this module)	6.61E-5			
Targets of MicroRNA ATGCAGT, MIR-217	1.08E-4			
Targets of MicroRNA TGTGCCTT, MIR-506	1.5E-4			
Genes with promoter regions around transcription start site containing the motif GGGCGGR which matches annotaion for SP1.	1.59E-4			
Up-regulated in fibroblasts at 6 hours following treatment with iterferon-alpha	2.01E-4			
Targets of MicroRNA TGTTTAC, MIR-30A-5p, MIR-30C, MIR-30D, MIR-30B, MIR-	2.23E-4			

#### Supplementary Table 4. PCC between differentially expressed TE-derived target genes and c-Myc

Gene Symbol & TE class/family	PCC	t	<i>P</i> value (Student's t-test)
PSMA5_Alu	0.63	6.03	1.54E-07
GORASP2_Alu	0.62	5.91	2.35E-07
XRCC5_Alu	0.61	5.79	3.71E-07
MAP4_Alu	0.43	3.51	925E-04
GNAI2_Alu	-0.63	-6.04	1.50E-07
ADD1_Alu	-0.54	-4.72	1.696E-05
SLC29A1_Alu	0.77	8.88	3.83E-12
DKC1_Alu	0.64	6.13	1.04E-07
VBP1_Alu	0.62	5.77	4.01E-07
KIAA0247_Alu	-0.58	-5.19	3.20E-06
OIP5_Alu	0.48	4.00	1.90E-04
AKAP1_Alu	0.79	9.60	2.84E-13
RBBP8_Alu	0.48	3.97	2.13E-04
SLC23A2_Alu	-0.40	-3.27	1.89E-03
DPM1_Alu	0.60	5.46	1.22E-06
LSM1_Alu	0.50	4.22	9.56E-05
JAK1_L1	-0.59	-5.43	1.38E-06
LRPPRC_L1	0.80	9.68	2.16E-13
TRIO_L1	-0.51	-4.37	5.77E-05
BAZ1B_L1	0.54	4.67	2.05E-05
MTAP_L1	0.70	7.19	2.06E-09
PRKCB1_L1	-0.52	-4.51	3.54E-05
RBBP8_L1	0.48	3.97	2.13E-04
ADARB1_L1	-0.46	-3.80	3.69E-04
ABCC4_L1	0.48	4.00	1.94E-04
MAN2A1_L1	-0.47	-3.96	2.19E-04
SPTLC2_L1	-0.38	-3.01	3.98E-03

## Supplementary Table 4(Continued). **PCC between differentially expressed TE-derived target genes and c-Myc**

Gene Symbol & TE class/family	PCC	t	<i>P</i> value (Student's t-test)
SLC20A1_MIR	0.46	3.80	3.75E-04
ITPR1_MIR	-0.66	-6.50	2.65E-08
CTSO_MIR	-0.40	-3.21	2.25E-03
MCCC2_MIR	0.73	7.83	1.86E-10
PGK1_MIR	0.55	4.82	1.22E-05
UROS_MIR	0.60	5.58	8.11E-07
SLC7A1_MIR	0.66	6.47	2.95E-08
ERH_MIR	0.63	5.99	1.77E-07
AKT2_MIR	0.60	5.54	9.27E-07
HCLS1_MIR	-0.63	-5.89	2.53E-07
ZNF330_MIR	0.70	7.19	2.01E-09
NOLC1_L2	0.83	10.75	4.89E-15
PRKCB1_L2	-0.52	-4.51	3.54E-05
POLR2F_L2	0.53	4.58	2.82E-05
CD151_L2	0.23	1.75	8.66E-02
VAMP2_L2	-0.59	-5.41	1.47E-06
PPT1_DNA	0.59	5.31	2.15E-06
XRCC2_DNA	0.53	4.58	2.79E-05
DDX10_DNA	0.74	8.06	7.82E-11
HELZ_DNA	-0.59	-5.42	1.42E-06
AFG3L2_DNA	0.68	6.73	1.11E-08
ADARB1_DNA	-0.46	-3.80	3.68E-04
FCGR2A_LTR	-0.47	-3.86	3.04E-04
SELL_LTR	-0.59	-5.37	1.73E-06
SNX3_LTR	-0.45	-3.75	4.30E-04
LAIR1_LTR	-0.41	-3.32	1.60E-03

Supplementary Table 5. Enriched annotations for differentially expressed target genes derived from specific TE class/family. Based on gene set enrichment analysis using MsigDB.

Genes with MIR derived c-Myc binding sites				
Functional annotations	Overlapping genes	P value		
Up-regulated by UV-B light in normal human epidermal keratinocytes	ITPR1 PGK1 ZNF330	1.39E-5		
G-alpha-q activates phospholipase C, resulting in calcium influx and increasing protein kinase C activity	ITPR1 AKT2	2.63E-5		
Genes related to PIP3 signaling in B lymphocytes	ITPR1 AKT2	4.37E-5		
Gi and Go proteins are members of the same family that transducer cell signals through both their alpha and beta subunits	ITPR1 AKT2	4.37E-5		
Members of the BCR (B cell antigen receptor) signaling pathway	ITPR1 AKT2	7.17E-5		
Genes with L1 derived c-Myc binding sites				
Functional annotations	Overlapping genes	P value		
Down-regulated following treatment of XPB/CS fibroblasts with 3J/m^2 UVC	LRPPRC TRIO ADARB1 MAN2A1 MTAP	4.89E-8		
EGF pathway	PRKCB1 JAK1	2.44E-5		
PDGF pathway	PRKCB1 JAK1	2.44E-5		
Genes up-regulated in fatal/refractory diffuse B-cell lymphoma and down-regulated in cured diffuse B-cell lymphoma	LRPPRC PRKCB1	4.62E-5		
Genes with Alu derived c-Myc binding sites				
Functional annotations	Overlapping genes	P value		
Down-regulated in response to glucose starvation	XRCC5 PSMA5 MAP4 OIP5 GORASP2	3.82E-9		
Nucleobase, nucleoside, nucleotide and nucleic acid metabolic process	XRCC5 SLC29A1 SLC23A2 LSM1 RBBP8 DKC1	5.54E-6		
Down-regulated in response to leusine starvation	XRCC5 PSMA5 SLC29A1	4.86E-5		

Supplementary Figure 4. Multiple alignment of all AluSx elements containing c-Myc binding sites.

TGGTA-AAACCCTGTCTCTACTAAAAATACAAA-AATTAGCCAAGTG	GGTGGCACGTGCCTTTTAATCCCAGCTACTCTGGAGGCTGAGGCAC	AGAATTGCTTGAAGCCAGGAGGTGAAGGTTGCAGCCAGCCAAG
TAGTG-GAGCCCTGTCTCTATGAAAAATACAAA-AA-AC	TAGCACGTGCCTTGTAGTCC-AGCTACTCAGGAGGCTGAGGTAG	JAGTAGGAGAATTGCTTGAACCCAGGAGGTAGAGGTTGCAGTGAGCCAAG
CGGTG-AAACCTACTAAAAATACAAA-A-TTAGCTGGGTG	GGTGCCACGTGCCTTGTAATCCCAGCTACTCAAGAGGCTGAGGCAG	JAGAATTGCTCAGACCCAGGAGATGGAGGTTGTGGTGAGCCAAG
TGGCA-AAACCCCCGCCACTACTAAAAATACAAA-GATTAGCCGGGCG	TGGAGCACGTGCTTTGTAATCCCAGGTACTCAGAAGGCTGAGGCAC	AGATTCGCTTGAACCCAGGAGGCGGAGGCTGCAGTGAGCCAAG
TGGCA-AAACCCCCTTTCTACTAAAGATACAAA-AATTAGCCAGGTG	GATGGCAGGCACCT-GTAATCTCAGCTACTTGGGAGACTAAGGCAT	AGGATCACTTGAGCCCAGGAGGCAGAGGTTACAATGAACTGAG
TGGTA-AAACCTCGTCTCTACTAAAAAACACAAA-AATTAGCCAGGCG	GGTAGCACGTGCCTTATAATCCCAGCTACTCAGGAGGCTGAGGCAG	ATAATTGCTTGAATCCAGGGGGGGGGAAGTTGCAGTGAGCTGAG
TGGCA-AAACCCCGTCTCTACCAAAAAA-TTTAGCTGGGCA	GGTAGCACGTGCCTTGTGATCCCAGCTATTCAGGAAGCTGAGGCAC	NGAATCGCTTGAGCCCGGGAGACAGAGGTTGCAGTGAGCTGAG
TGATG-AAACCCTGTCTCTACTAAAAATACAAA-TATTAACCGGACA	AGTAGCACGTGCCTTTTTAATTCCGGCTACTCCGGAGGCTGAGGCAC	IAGACTGCTCTAACCCAGGAGGCGGAGGTTGCAATGAGCTGAA
TGGTG-AAACCCTGTCTCTACTAAAAACACAAA-AATTAGCCAGGC	GGTGGCACGTGCCTTGTGATCCCAGCTACTCAGGAGGCTGAGGCAG	AGAACC-CTTGAACCTGGGAGGCAGAGGTTGCAGTGAGCCGAG
TGGTGGAAACCCCTTCTCTACTAAAAATATAAAAATTAGTTAGGCG	GCTGGTGCATG-CCTGTAATCGCAGCTACTTGGGAGGCTGAGGCAA	AGAATCACTTGAACCCAGGAGGCGGAGGTTGCAGTGAGCCGAG
TGGTG-AAACCCCATCTCTACTAAAGATACAGAAATTAGCTGGGCA	GGTGGCACGTGGCTTGTAATCCCAGCTATTGGGGAGGCTGAGGCAG	JAGAATCGTTTGAACCCAGGAGCTGGAGGTTGCAGTGAGCCAAG
TGGTG-AAACCCTGTCTCTACTAAAAATACAAAAAATTTTAGCTGGGCA	GGTGCCACGTGCCTTGTAGTGG-GACTACTCTGGCGGCTGAGGGAG	JAGAATCGCTTGAACCTGGTAGGTGGAGGTTGCAGTGAGCTGAG
GGGTG-AAACCCCGTCTCTACTAAAAAACACAAAAAAATTTACCCAGGCA	GGTGGCACGTGCTTTGTAATCCCAGCTACCAGGAGGCTGAGGCAG	AGAATCACTTGAACCCAGGAGGCGGAGGTTACAGTAAACCAAG
TGGCG-AAACCCTGTCTCTACTAAAAATACAAAAAATTAGCCAAGCA	GGTAGCACGTGCCTTGTAATCCCAGCTACTTGGGAGGGTGAGGCAG	AGAATCACTTGAACCCAGGAGGCGGAGGCTGCAATGAGCTGAG
TGGTG-AAACCCTGTCTCTATTAAAAATACAAAAATTAGCTGGGCG	GGTGGCACGTGCCT-GTAATCCCAGCTCCTTGGGAGGCTGAG	AATCACTTGAACTTGGGAGATGGAGGTTGCAGTGAGCCGAG
TGGAG-AAACCCCGTCTCTGCTAAAAATACAAAAAATTAGCTGGGTA	( AGT-GCACGTGCTTTGTAGTTCTAGCTACTCGGGAGGCTGAGGCAG	JAGAATGGCTTGAACCTGGGAGGGGGGGGGGGGGGG
TAGCG-AAATCCCCATCTCTACTAAAAATACAGAAATTAGCCAAGGG	GGTGGCACGTGCTTTGTAATCCCAGCTACTCGGGAGGCTGAGGCAG	JAGAATCGCTTGAACTTGGTAGGTGGAGGTTGCAGTGAGCCGAG
TAAATTAAATTAAATAAATAA-ATAAATAAAAATAAA-TTAGCTGGGTG	AGTGCCACGTGCCTTGTAATCCCAGCTACTCAGGAGGCTGAGGCAG	AGAATCACTTGAACCCAGGAGGCAGAGTTGCAGTGAGCAGAG
chr6 106634084-106634389	GGTGGCACGTGCCT	GGCTGAGGCAC 191
$h^{-}$	TAGCACGTGCCT TGTAGTCC-AGCTACTCAGGA	GGCTGAGGTAG 178
chr7 96605117 = 96605406	CCTCCCACCTCCCTTCTTATCCCACCTACTCAACA	CCCTCA CCCCAC 177
abr21 44105270-44105677	COTOCOLOCITICIANI CCCASCINCICANON	CCCTCA ATCACCCAC 194
		COCTORATOROGOCAG 194
CHT9_135954613-135954918	TGGAGCACGIGCITIGTAATCCCAGGTACTCAGAA	GGCTGAGGCAC 192
chr11_101893114-101893406	GATGGCAGGCACCT -GTAATCTCAGCTACTTGGGA	GACTAAGGCAT 190
chr19_43783280-43783585	GGTAGCACGTGCCT FATAATCCCAGCTACTCAGGA	GGCTGAGGCAG 191
chrX_154112156-154112453	GGTAGCACGTGCCT IGTGATCCCAGCTATTCAGGA	AGCTGAGGCAC 185
chr19_23047502-23047807	AGTAGCACGTGCCT	GGCTGAGGCAC 191
chr10_7596858-7597236	GGTGGCACGTGCCCCCATAATCTCAGCTACTCGGGA	GGCTGAGGCAA 191
chr17_9826537-9826936	GGTGGCACGTGCCT	GGCTGAGGCAG 191
chrX 40714147-40714438	GCTGGTGCATG-CCTGTAATCGCAGCTACTTGGGA	GGCTGAGGCAA 190
chr19 54780867-54781169	CCTCCCACCTCCCTTCTCCCACCTATTCCCCC	CCCTCA CCCAC 191
abr17 = 52515512 = 52515911	do i doche i doci i di hai eccade i ai i dodde	
	CCTCCCACCTCCCT	CCCTCA =CCCAC 191
chr7 120210512 120210022	GG TGCCACGTGCCT IGTAGTGG-GACTACTCTGGC	GGCTGAGGGAG 191
chr7_138318512-138318823	GGTGCCACGTGCCTIGTAGTGG-GACTACTCTGGC GGTGCCACGTGCTTIGTAATCCCAGCTACTCAGGA	GGCTGAGGGAG 193 GGCTGAGGCAG 193
chr7_138318512-138318823 chr8_97336761-97337062	GGTGCCACGTGCCT IGTAGTGG-GACTACTCTGGC GGTGGCACGTGCTT IGTAATCCCAGCTACTCAGGA GG <mark>TGGCACGTGCTT</mark> IGTAATCTCAGCTACCAGGA	GGCTGAGGGAG 193 GGCTGAGGCAG 193 GGCTGAGGCAG 191
chr7_138318512-138318823 chr8_97336761-97337062 chr7_97850190-97850445	GGTGCCACGTGCCT IGTAGTGG-GACTACTCTGGC GGTGGCACGTGCTT IGTAATCCCAGCTACTCAGGA GGTGGCACGTGCTT IGTAATCTCAGCTACCAGGA GGTAGCACGTGCCT IGTAATCCCAGCTACTTGGGA	GGCTGAGGGAG 193 GGCTGAGGCAG 193 GGCTGAGGCAG 191 GGGTGAGGCAG 130
chr7_138318512-138318823 chr8_97336761-97337062 chr7_97850190-97850445 chrX_153651656-153651962	GGTGCCACGTGCCT IGTAGTGG-GACTACTCTGGC GGTGGCACGTGCTT IGTAATCCCAGCTACTCAGGA GGTGGCACGTGCTT IGTAATCCCAGCTACCAGGA GGTAGCACGTGCCT IGTAATCCCAGCTACTTGGGA GGTGGCACGTGCCT -GTAATCCCAGCTCCTTGGGA	GGCTGAGGGAG 193 GGCTGAGGCAG 193 GGCTGAGGCAG 191 GGGTGAGGCAG 130 GGCTGAGCCAG 130
chr7_138318512-138318823 chr8_97336761-97337062 chr7_97850190-97850445 chrX_153651656-153651962 chr12_57246394-57246669	GGTGGCACGTGCCT IGTAGTGG-GACTACTCTGGC GGTGGCACGTGCTT IGTAATCCCAGCTACTCAGGA GGTGGCACGTGCTT IGTAATCTCAGCTACCAGGA GGTGGCACGTGCCT IGTAATCCCAGCTACTTGGGA GGTGGCACGTGCCT -GTAATCCCAGCTACTTGGGA AGT-GCACGTGCTT IGTAGTTCTAGCTACTCGGGA	GGCTGAGGCAG 193 GGCTGAGGCAG 193 GGCTGAGGCAG 191 GGGTGAGCCAG 130 GGCTGAG 187 GGCTGAGCCAG 157
chr7_138318512-138318823 chr8_97336761-97337062 chr7_97850190-97850445 chrX_153651656-153651962 chr12_57246394-57246669 chr13_31102575-31102879	GGTGCCACGTGCCT IGTAGTGG-GACTACTCTGGC GGTGGCACGTGCTT IGTAATCCCAGCTACTCAGGA GGTGGCACGTGCTT IGTAATCTCAGCTACCAGGA GGTGGCACGTGCCT IGTAATCCCAGCTACTTGGGA GGTGGCACGTGCCT -GTAATCCCAGCTACTTGGGA AGT-GCACGTGCTT IGTAGTCTAGCTACTCGGGA GGTGGCACGTGCTT IGTAATCCCAGCTACTCGGGA	GGCTGAGGCAG 193 GGCTGAGGCAG 193 GGCTGAGGCAG 191 GGGTGAGGCAG 130 GGCTGAGGCAG 157 GGCTGAGGCAG 191
chr7_138318512-138318823 chr8_97336761-97337062 chr7_97850190-97850445 chrX_153651656-153651962 chr12_57246394-57246669 chr13_31102575-31102879 chr19_2094063-2094229	GGTGCCACGTGCCT IGTAGTGG-GACTACTCTGGC GGTGGCACGTGCTT IGTAATCCCAGGCTACTCAGGA GGTGGCACGTGCTT IGTAATCTCAGCTACCAGGA GGTGGCACGTGCCT IGTAATCCCAGCTACTTGGGA AGT-GCACGTGCCT IGTAATCCCAGCTACTCGGGA GGTGGCACGTGCCT IGTAGTTCTAGCTACTCGGGA GGTGGCACGTGCCT IGTAGTCCCAGCTACTCGGA	GGCTGAGGGAG 193 GGCTGAGGCAG 193 GGCTGAGGCAG 191 GGGTGAGGCAG 130 GGCTGAGGCAG 157 GGCTGAGGCAG 157 AGCTGAGGCAG 191 AGCTGAGGCAG 58
chr7_138318512-138318823 chr8_97336761-97337062 chr7_97850190-97850445 chrX_153651656-153651962 chr12_57246394-57246669 chr13_31102575-31102879 chr19_2094063-2094229 chr1_8633557-8633752	GGTGCCACGTGCCT IGTAATCCCAGCTATTGGG GGTGCACGTGCTT IGTAATCCCAGCTACTCAGGA GGTGGCACGTGCTT IGTAATCTCAGCTACCAGGA GGTGGCACGTGCCT IGTAATCCCAGCTACTTGGGA AGT-GCACGTGCCT IGTAATCCCAGCTACTTGGGA GGTGGCACGTGCTT IGTAATCCCAGCTACTCGGGA GGTGGCACGTGCTT IGTAATCCCAGCTACTCGGGA GGTGGCACGTGCCT IGTAATCCCAGCTACTCGGA	GGCTGAGGGAG 193 GGCTGAGGCAG 193 GGCTGAGGCAG 191 GGGTGAGGCAG 130 GGCTGAGGCAG 157 GGCTGAGGCAG 157 GGCTGAGGCAG 191 AGCTGAGGCAG 58 GGCTGAGGCAG 95

**C-Myc binding sites** 

Additional files provided as Supplementary Information. Three BED format text files are provided so that the primary data can be visualized with the UCSC Genome Browser.

**PotentialGeneTargets.bed** Human genome reference sequence (hg18) coordinates and RefSeq identifiers for the 1,550 genes with proximal TE-derived c-Myc binding sites.

**TEsBoundbycMyc\_0.01.bed** Human genome reference sequence (hg18) coordinates for 4,564 TE sequences experimentally characterized to be bound by c-Myc. 0.01 refers to the *P*-value threshold used by Clover to identify c-Myc binding site motifs.

**TEsBoundbycMyc\_0.001.bed** Human genome reference sequence (hg18) coordinates for 816 TE sequences experimentally characterized to be bound by c-Myc. 0.001 refers to the *P*-value threshold used by Clover to identify c-Myc binding site motifs.